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doi:10.1016/j.ejvs.2010.03.034Abstract Objective: To review the psychometric validation of the Chronic Venous dIsease
quality of life Questionnaire (CIVIQ-20) in the countries that have used it since 1996.
Design: Prospective, clinical, international study in 18 countries.
Patients: Patients with venous disease of the lower limb in the clinical, aetiological, anatom-
ical and pathophysiological (CEAP) clinical stages C0s to C4 presenting to surgical outpatient
departments and general practices and receiving drug treatment for 6 months.
Methods: Quantification of symptoms on a four-point scale and pain on a visual analogue scale,
and self-administration of CIVIQ-20 to patients before visit (baseline, 2, 4 and 6 months).
Results: In 3956 patients, CIVIQ-20 showed good internal consistency and reliability (above
0.80) through testeretest correlations. The discriminating power of items was good in known
groups of patients. Factor analysis identified physical, psychological and pain factors as impor-
tant, but revealed instability of the social factor. CIVIQ-20 was highly sensitive to changes in
the quality of life of patients clinically improved after drug treatment. CONCLUSION: CIVIQ-
20 is valuable in assessing treatment effects in longitudinal, multinational studies, but compar-
isons of different populations should use the global score rather than scores per dimension.
ª 2010 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.The World Health Organization has defined quality of life
(QoL) as a state of complete physical, mental and social
well-being, and not merely the absence of disease.)1 44 39 16 90; fax: þ33 (0)1
@wanadoo.fr (R. Launois).
ty for Vascular Surgery. PublisheDetermination of QoL has been accorded increasing scien-
tific attention in recent years, mainly because the question
of direct benefit of medical treatment for patients has been
raised.
Chronic venous disease (CVD) needs specific scales of
measurement for many reasons. First, it is common;1
second, physicians usually underestimate the negative
impact CVD may have on patients’ daily life;2 and third, asd by Elsevier Ltd. All rights reserved.
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caused by CVD may add social impairment to the physical
and psychological ones. A 20-item self-reported scale was
created and validated in France in 1996,3 as a sensitive
instrument to capture the key dimensions of QoL specifi-
cally impaired by CVD: the ChronIc Venous dIsease quality
of life Questionnaire (CIVIQ-20). In the original French
version, the five conditions required for validation (rele-
vance, acceptability, reliability, construct validity and
sensitivity) were met. Four dimensions of the CIVIQ-20 were
identified: physical (four items), psychological (nine items),
social (three items) and pain (four items). Details of the
phases of its development are described elsewhere.3 The
CIVIQ-20 was validated in its French version and thus could
not be generalised to other countries.
Objective of the Study
The purpose of the present analysis, therefore, was to
review the psychometric validation of CIVIQ-20 through the
Reflux assEssment and quaLity of lIfe improvEment with
micronised Flavonoids (RELIEF) study.
RELIEF was a prospective, clinical, epidemiological,
multicentre, international study, the primary objective of
which was the assessment of the clinical effect of drug
therapy, while the secondary objective was the measure-
ment of the quality of life (QoL) of patients before and
after drug treatment with micronised, purified flavonoid
fraction (MPFF, Daflon 500 mg, Servier, France). Clinical
and QoL results of the RELIEF study are published
elsewhere.4
In the present analysis, we focussed exclusively on QoL
parameters by verifying that the psychometric properties
of CIVIQ-20 in the country of origin (France) were also
found in the 18 countries of the RELIEF study (Argentina,
Brazil, Brunei, Czech Republic, Egypt, Hong Kong, Hungary,
India, Malaysia, Philippines, Poland, Russia, Singapore,
Slovakia, Spain, Sri Lanka, Turkey and Venezuela).
Method
From February 1997 to February 1999, patients with CVD-
related symptoms and/or signs, who presented in surgical
outpatient departments and who signed an informed
consent form, participated in the QoL section of the RELIEF
study. CVD signs were reported according to the clinical,
aetiological, anatomical and pathophysiological (CEAP)
classification, which categorises affected legs into seven
clinical classes designated C0s to C6.5 Only patients over 18
years of age and clinically defined as C0s to C4 were
included.
Before each visit, patients completed the self-ques-
tionnaire CIVIQ-20 in the waiting room at the selection visit
(day 15), day 0 (day of treatment start with 1000 mg of
MPFF daily for 6 months), day 60, day 120 and day 180. The
secretary handed out the questionnaire and collected it
once completed. No particular assistance was to be
provided to patients. This procedure was chosen on purpose
to avoid any interference from an investigator.
At study times, symptom severity was quantified using
a four-point scale (0 Z absent, 1 Z mild, 2 Z significant,3 Z severe) for sensation of swelling, cramps and leg
heaviness. Leg pain was assessed with a 10-cm visual
analogue scale.
The scores of CIVIQ-20 ranged from 0, the worst score,
to 100, the best score.
Statistical Analysis
Statistical analysis was carried out by MAPI Values (Lyon,
France) on an IBM-compatible computer using SAS software
release 6.12 (SAS Institute, Cary, NC, USA).
Results
Patient characteristics
At baseline, the majority of the 4048 patients enrolled in
the QoL study were of Caucasian ethnic origin (77.9%),
women (81.1%), professionally active (61.8% were
employed full-time) and mean age 45.6 standard devia-
tion (SD) 12.3 years. They had experienced CVD for 12.4
SD 9.8 years and were defined as C0seC2 of the CEAP
clinical classification in 60.4% of cases and C3eC4 in
39.4%. The most frequently encountered complaints were
pain (99.5% of patients) and heaviness (94%), sensation of
swelling (78%) and cramps (69%). Using the four-point
scale, heaviness was scored 3 or 4 (severe or significant)
in 57.2% cases while swelling and cramps were usually of
mild intensity or even not present (67.8% and 70%,
respectively, were scored 0 or 1). As regards pain, the
mean value at baseline was 3.8 SD 2.5 cm on visual
analogue scale.
Acceptability
The acceptability of a questionnaire depends on the quality
of its construction. The acceptability of CIVIQ-20 was
assessed from the response rates to each of the questions
and by the number of questionnaires completed.
All 4048 patients completed CIVIQ-20 at least once. Only
53 did not complete it at baseline and were removed from
the database. Out of the 3995 patients with a usable
baseline questionnaire, 91.5% (n Z 3656) had five usable
QoL assessments (one assessment at each of the five plan-
ned visits) and 99.0% (n Z 3956) had at least one other
usable CIVIQ-20 after baseline and could therefore be
included in the longitudinal analyses.
As regards the responses of the 4048 patients who
completed CIVIQ-20 at least once, the following results
were obtained: 8.0% (D0eday 0) and 12.6% (D180eday 180)
of the questionnaires had at least one missing value, and
the average percentages of missing data by item were
1.67% (D0) and 7.34% (D180).
Reliability
A scale is reliable if it produces similar results in measuring
the same phenomenon on a number of occasions. Internal
consistency and testeretest reproducibility are commonly
used to determine reliability.
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Internal consistency verifies that items in a dimension
remain homogeneous even if they are worded differently. It
is assessed using Cronbach’s alpha coefficients, which are
considered acceptable if >0.70. CIVIQ-20 gave a Cronbach’s
alpha coefficient of 0.94 for the global index, and 0.86,
0.89, 0.83 and 0.76, respectively, for the physical,
psychological, pain and social dimension. These results
confirm the satisfactory internal consistency of the scale,
but display less homogeneity for the social dimension items
than for those of the other dimensions. A floor effect was
seen in 0.9e8.5% of patients, and a ceiling effect in
0.0e0.3%, meaning that most items dealing with the
disease are covered by the scale.
Testeretest reproducibility
Reproducibility means that the answers to the same ques-
tionnaire remain unchanged in clinically stable patients. It
was assessed over the washout period (between De15 and
D0) in stable patients, that is, patients for whom symptoms
did not improve or deteriorate, and CEAP class remained
stable during this period. The number of patients qualified
as stable ranged from 3749 (unchanged CEAP clinical stage)
to 3147 patients (unchanged heaviness score). In general,
2406 patients (61%) qualified as stable over the screening
period. Retest reliability showed a high correlation,
r > 0.80, in dimension scores at a 2-week interval (Table 1).
Construct validity
An instrument is said to be accurate when there is
a congruence between the measuring operations and the
theoretical items these operations are designed to
measure.
Multi-trait/multi-item analysis
The multi-trait/multi-item matrix analyses the correlation
of each item with its own dimension. For each item, two
correlation coefficients are calculated: R1 assesses the
correlation between an item and the dimension it belongs
to, and R2 the correlation with the other dimensions. If R1
is >0.40, the convergent validity between an item and its
dimension is considered as good. If R1 is >R2, the item
matches its dimension and its discriminating validity is
good. As shown in Table 2, all items correlate successfully
with the dimension they belong to (R1 > 0.40 for all items,Table 1 Testeretest reproducibility of the CIVIQ-20 global inde
Clinical parameter Number of stable pa
(MD)
CEAP (N Z 3749) 3635 (114)
Swelling (N Z 3250) 3153 (97)
Heaviness (N Z 3147) 3050 (97)
Cramps (N Z 3075) 3069 (96)
Pain (N Z 3714) 3605 (109)
All parameters together (N Z 2406) 2339 (67)
a Change was expressed by the difference between Global Index (G
SD, standard deviation; ICC: intra-class correlation coefficient.success rate: 100%), meaning that the scale structure of
CIVIQ-20 is good. Regarding the discriminating validity of
the items, all but two items correlate with their own
dimensions (R1 > R2). The success rate (SR) was 100% for
the items in the physical and psychological dimensions.
Weaknesses were found in the social dimension (SR 67%)
and pain dimension (SR 75%).
In the Czech Republic, Poland, and Spain, all item-scale
correlations were higher than 0.40, confirming the good
convergent validity. Flaws were seen in the discriminating
validity of items mainly in the social dimension for which SR
was 67%, 0% and 33%, respectively in Czech Republic,
Poland and Spain, while SR for items in the other dimen-
sions ranged from 75% to 100%. These analyses questioned
the match between the set of items in CIVIQ-20 and the
social dimension.
Factorial structure
To confirm the factorial structure of the instrument, prin-
cipal axis factoringwith Promax rotationwas performedwith
a four-factor model, the number of factors corresponding to
the number of dimensions in CIVIQ-20. Fifty-seven percent of
the variance was explained (Table 3). The first factor has
three items from the original definition and can be inter-
preted as physical, but is not fully consistent with the initial
definition of the physical dimension of CIVIQ-20 since one
item was from the original psychological dimension (‘to get
tired easily’) and two were from the social dimension (‘to go
out in the evening’ and ‘to practice a sport’). The second
factor can be seen as psychological, with loading of seven of
the nine items from the original psychological dimension of
CIVIQ-20. The four items from the original pain dimension
load on the third factor, which can be clearly identified as
pain. The fourth factor ismixed,with one itemof the original
social dimension and two items from other dimensions of the
CIVIQ-20 (physical and psychological).
Principal axis factoring was applied separately to the
data from Czech Republic, Poland and Spain. In Czech
Republic and Poland, factors 1, 2 and 3 might be inter-
preted respectively as physical, psychological and pain
factors, with most items from the original dimensions of
CIVIQ-20 loading on these factors (three out the four for the
physical, eight of the nine for the psychological and four for
the pain dimension), but the fourth factor could not be
interpreted. In Spain, factors were not easy to interpret as
many items were mixed.x according to the clinical parameters of the RELIEF study.
tients Changea in global index
(Mean and SD) ICC P value
0.59 SD 6.74 0.9319 0.0001
0.64 SD 6.40 0.9385 0.0001
0.62 SD 6.10 0.9441 0.0001
0.43 SD 6.20 0.9427 0.0001
0.57 SD 6.47 0.9376 0.0001
0.54 SD 5.38 0.9561 0.0001
I) at selection (D-15) and GI at baseline (D0); MD, missing data;
Table 2 Multi-trait/multi-item analysis of the CIVIQ-20 in the 18 countries of the RELIEF Study.
Physical dimension Psychological dimension Social dimension Pain dimension
Physical items R1 R2 R2 R2
1 To climb stairs DD   
2 To crouch/to kneel DD   
3 To walk briskly DD   
4 To do the housework D   
Psychological items R2 R1 R2 R2
1 Feel on edge  DD  
2 Get tired easily  DD  
3 Feel like a burden to people  DD  
4 Must take precautions  DD  
5 Embarrassed to show one’s legs  D  
6 Easily irritable  DD  
7 Feel handicapped  DD  
8 Difficulty getting going in the morning  DD  
9 Do not feel like going out  DD  
Social items R2 R2 R1 R2
1 To go out in the evening   DD 
2 To practice a sport DD L þ 
3 To travel by car/bus/plane   DD 
Pain items R2 R2 R2 R1
1 Pain in legs    DD
2 Interferes with work    DD
3 Sleep badly    D
4 To stand for a long time DD   þ
Convergent validity (R1>0.40) 100% 100% 100% 100%
Discriminating validity (success rate of R1>R2) 100% 100% 67% 75%
Correlation factors: R1, correlation between an item and its own dimension: þ, >0.40; þþ, >0.60; R2, correlation between an item and
a dimension other than its own: þ, >0.40; þþ, >0.60; R1>R2 is marked by e.
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particularly with regard to the social dimension.
Known group differences
To verify whether the scale is able to discriminate between
severity states of chronic venous disease, we used Spear-
man’s correlation coefficient to search for significant
negative associations in stable patients (between day 15
and day 0) with known differences in symptom scores and
CEAP classes at baseline. Significant associations
(PZ 0.0001) were found in all groups of patients (Table 4).
For all clinical parameters, the highest association was
found in the ‘pain dimension’. The highest association
(rZ 0.46400) was observed with the visual analogue scale
pain parameter (not shown), and the lowest with the CEAP.
For the four dimensions and for the global index (GI),
a significant difference was seen in the mean scores
according to the CEAP clinical classes at baseline. The
mean variation of GI between C0s and C4 was 16 points
(Table 5).
Responsiveness
Longitudinal changes in CIVIQ-20 scores after treatment
One important aspect of QoL scales is their ability to reflect
changes in the clinical variables that occur during
treatment.The end points used for clinical improvement after
treatment were decrease in CVD-related symptoms and
change in CEAP class. Improvement in swelling, heaviness
and cramps was defined as a decrease of at least one point
on the four-point scale. For pain, a decrease on the visual
analogue scale of 2.5e5 cm and of more than 5 cm was
used for improvement and great improvement, respec-
tively. As regards the clinical signs, their improvement was
assessed by a decrease of one class of the CEAP. Of the
3956 patients included in the longitudinal analysis between
day 0 and day 180, on average, 63.3% had improved
symptoms, 34.4% were stable and 2.3% had worsened;
80.2% were stable as regards the CEAP, 18.1% had improved
and 1.7% had worsened. This confirms that the CEAP cannot
serve the purpose of quantifying changes in response to
treatment.
All patients included, the GI of CIVIQ-20 was a mean
of 64.1 SD 18.5 at day 0, 73.1 SD 17.2 at day 60, 78.2 SD
16.3 at day 120 and 82.1 SD 15.7 at day 180, meaning
that the patients’ QoL improved overall after treatment
(18 points on GI between D0 and D180; P < 0.0001). The
greatest QoL improvement was seen after 2 months, but
increased further after 4 and 6 months. The highly
statistically significant differences in scores (P < 0.0001)
between day 0 and day 180 were 18.80 for ‘physical’,
14.11 for ‘psychological’, 17.17 for ‘social’ and 24.63 for
‘pain’.
Table 3 Factorial structure of the CIVIQ-20 in the 18 countries of the RELIEF study.
Principal axis factoring-EQUAMAX-PAIRWISE-KMO Z 0.96% of variance explained Z 57% Factor 1 Factor 2 Factor 3 Factor 4
Physical items
1 To climb stairs DD L L L
2 To crouch/to kneel DD L L L
3 To walk briskly DD L L L
4 To do the housework L L L D
Psychological items
1 Feel on edge L D L L
2 Get tired easily D L L L
3 Feel like a burden to people L DD L L
4 Must take precautions L L L D
5 Embarrassed to show one’s legs L D L L
6 Easily irritable L DD L L
7 Feel handicapped L DD L L
8 Difficulty getting going in the morning L D L L
9 Do not feel like going out L D L L
Social items
1 To go out in the evening D L L L
2 To practice a sport D L L L
3 To travel by car/bus/plane L L L D
Pain items
1 Pain in legs L L DD L
2 Interferes with work L L DD L
3 Sleep badly L L D L
4 To stand for a long time L L D e
Factor loadings: , 0.40; þ, >0.40; þþ, >0.60.
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CIVIQ-20 scores was found over time after treatment and
was correlated with clinical improvement (Table 6).
Sensitivity (effect size)
A scale is considered sensitive when it detects changes in
a given variable over time and above the imprecision due to
measurement error. The sensitivity to change over time was
assessed by the effect size.6 Table 6 shows effect sizes
ranging from 1.24 for heaviness to 1.73 for pain.
Discussion
Numerous specific scales for CVD have been developed in
the past 20 years. This may reflect the difficulty of finding
an instrument applicable to the wider spectrum of CVD.Table 4 Known group differences at baseline according to sym
Clinical parameter Global Index (mean and SD) in patients suffer
Milda Severeb
CEAP 68.1 SD 19.1 59.1 SD19.9
Swelling 73.8 SD 15.1 45.7 SD 19.4
Heaviness 77.9 SD 15.4 47.8 SD 19.1
Cramps 71.5 SD 16.7 52.2 SD 20.5
a Mild was defined as follows: clinical CEAP classes, C0s to C2; swel
b Severe was defined as follows: clinical CEAP classes, C3 to C4; swMost of the scales have been used for longitudinal
comparison in randomised clinical trials. These scales must
be able to detect important changes in the patients’ QoL
after intervention.
The responsiveness of CIVIQ-20 is good and its sensitivity
to change high, particularly in the pain dimension. Never-
theless, the demonstration of the responsiveness of CIVIQ-
20 related only to symptom improvement as shown in Table
6; other quantifiable variables able to change with therapy
would have been welcome. It is unfortunate that the
quantifiable disease severity scoring system, which could
have served this purpose, was proposed by Rutherford after
the RELIEF study was set up,7 so that at the time of the
study, symptoms were the only clinical parameters that
were able to change with pharmacological treatment.
The CIVIQ-20 is well suited to longitudinal studies as it is
relatively short, has a five-point Likert scale format makingptoms and signs.
ing from CVD of Spearman’s correlation
coefficient
P value
(Wilcoxon)
0.22032 0.0001
0.38561 0.0001
0.41706 0.0001
0.33244 0.0001
ling, heaviness, cramps, scored 0 or 1.
elling, heaviness, cramps, scored 3 or 4.
Table 5 Known group differences at baseline according to the clinical CEAP classes.
Clinical CEAP class Physical dimension Psychological dimension Social dimension Pain dimension Global Score
C0s (N Z 103) 66.90 75.48 69.19 60.53 70.06
C1 (N Z 730) 67.13 72.95 70.65 58.42 68.49
C2 (N Z 1557) 66.34 72.01 69.70 58.16 67.84
C3 (N Z 1028) 57.66 64.29 60.40 50.75 59.70
C4 (N Z 522) 54.60 62.21 59.03 50.82 57.95
P (ANOVA) <0.001 <0.001 <0.001 <0.001 <0.001
788 R. Launois et al.it more sensitive than a binary response format and has no
items showing a floor or ceiling effect. Thus, the ability of
CIVIQ-20 to detect change makes it a good QoL scale for use
in randomised clinical trials. This is confirmed by extensive
use of CIVIQ-20 in recent years, to compare the effect of
surgery techniques for varicose veins,8e14 or after venous
stenting,15 or to assess the efficacy of compression
therapy,16,17 vein electrostimulation,18 drug therapy,4,19e21
or physical therapy.22 Most of these trials were conducted
in C2 to C5 patients. Some included C0s and C1
patients,4,16e18,21 but none include C6 patients. This is
because the scale was deliberately not targeted towards
patients with venous ulcers, as items that are relevant to
patients with varicose veins or oedema do not fit patients
with venous ulcer. While most C0s to C4 patients report
limited social or physical activities and psychological frus-
tration such as not being able to do sport or to travel by bus
or plane, and feel embarrassed to show their legs; patients
with ulcers, who are elderly for the most, are less likely to
complain about such things. It is questionable whether it is
realistic to require the construction of a single scale with
a set of items covering the full spectrum of CVD. As pointed
out by Hyland, “QoL scales are not like thermometers or
spirometers, where the reading is independent of the type
of patient.”23
Regarding its psychometric properties in the 18 countries
of the RELIEF study, CIVIQ-20 has been shown to be accept-
able to patients and easy to complete, to have a high level of
reliability and to provide good discrimination between the
severity of symptoms and the clinical CEAP classes. Because
CIVIQ-20was developed by taking into account complaints of
CVD patients, it reflects the importance they attach to each
complaint and the wording they use to express the unpleas-
antness. Being in symbiosis with patients’ concerns, it is not
surprising that the questionnaire was easily completed, and
this is one of the strengths of CIVIQ-20.Table 6 Responsiveness of the CIVIQ-20 global index to change
Clinical parameter Clinical evolution Number of
Swelling* Improved 2310
Heaviness* Improved 3014
Cramps* Improved 2374
Pain** Much improved 442
Improved 1892
Improvement* was defined as a decrease of one class for swelling, hea
to change in score (10-cm visual analogue scale): much improved ZIt is noteworthy that the CIVIQ-20 was able to discrimi-
nate between severities of CVD as shown in Tables 4 and 5,
even if the need for a good discriminative instrument in
CVD is met by the CEAP classification. The CEAP is consid-
ered to be an excellent descriptive and discriminative tool,
allowing the categorisation of CVD patients into seven
classes of progressive severity, but categorisation of
patients is based on physical parameters only in the CEAP,
while it relates to physical, psychological and social vari-
ables in CIVIQ-20.
In some studies, CIVIQ-20 has correlated well with other
QoL tests, that is, the Short Form36 Health Survey (SF-36)
and SF-12.16,21 This is another reason for selecting it in
longitudinal studies.
To our knowledge, CIVIQ-20 is the only specific scale for
CVD to have used item and factor analysis to demonstrate
to what extent the items are convergent with their
dimension and if they have a high factor loading. This
analysis revealed the lack of stability of the scale in its
social dimension. Flaws in the social dimension were also
seen in the Czech Republic, Poland and Spain. This raised
the question of whether this was due to cultural differences
or other reasons, such as cumbersome translation. During
the cross-cultural adaptation of CIVIQ-20, we had to modify
the ways in which some questions were expressed to adapt
the questionnaire to different cultural contexts; and, yet,
it is not granted that we succeeded in the cross-cultural
validation of the social items. In a seminal article, Ware
considered that the definition of personal health should be
restricted to physical and mental components, because
“.physical and mental variables are similar in that they
‘end at the skin’. They do not directly involve other people
or factors outside the individual,”24 and that the social
component is difficult to grasp in cross-cultural validation
processes. A shortened version of the instrument made of
14 questions (CIVIQ-14) of which the factorial stability hasover time.
patients Change in Global Index
between D180 and D0;
mean and SD
Effect size
21.1 SD 16.8 1.26
20.1 SD 16.2 1.24
21.1 SD 16.4 1.29
29.2 SD 16.9 1.73
23.8 SD 16.2 1.46
viness and cramps; for pain, improvement** was defined according
decrease of 5 cm or more, improved Z decrease of 2.5e5 cm.
International Validation of CIVIQ-20 789been rigorously validated is pending. This short version will
make up for the instability found with CIVIQ-20. In the
meantime, our recommendation is to use the easy-to-
handle GI of CIVIQ-20 in multinational studies.
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